Relation of the rs6923761 Gene Variant in Glucagon-Like Peptide 1 Receptor to Metabolic Syndrome in Obese Subjects

Background: The role of glucagon-like peptide 1 (GLP-1) variants in metabolic syndrome (MS) and its components remains unclear in obese subjects. Objective: The aim of our study was to evaluate the relationship of rs6923761 with MS and its components in obese subjects. Design: A population of 1,122 obese subjects was analyzed in a cross-sectional survey. To estimate the prevalence of MS, we considered the definitions of the Adult Treatment Panel III. Results: Five hundred and forty-eight patients (48.8%) had the GG genotype (wild-type group), whereas 487 patients (43.4%) had the GA genotype and 87 patients (7.8%) the AA genotype. The mean age was 48.9 ± 12.8 years. The prevalence of MS was 47.4% (532 patients), and 52.6% of patients had no MS (n = 590). The odds ratio of MS for the wild-type versus the mutant genotype was 1.02, with a 95% confidence interval of 0.88-1.12. Body mass index, weight, fat mass, waist circumference, and waist to hip ratio were lower in the mutant than in the wild-type group in patients with and without MS. Conclusion: The GLP-1 receptor variant rs6923761 was found to be associated with decreased weight and anthropometric parameters in A allele carriers with and without MS. MS or its components were not associated with this polymorphism in obese adults.